Sucampo and Takeda Introduce Amitiza 8mcg Capsules in US
Posted on: Wednesday, 28 May 2008, 12:00 CDT
Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America have announced that Amitiza 8mcg capsules are now available by prescription in pharmacies across the US for the treatment of irritable bowel syndrome with constipation in women 18 years and older.
Amitiza has a mechanism of action that works locally in the intestine to increase fluid secretion, resulting in increased passage of stool and alleviating symptoms associated with chronic idiopathic constipation.
Amitiza was developed by Sucampo Pharmaceuticals and is co-marketed in the US by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America.
Ryuji Ueno, founder, chairman and CEO of Sucampo, said: "I am very pleased with the quick commercial launch of Amitiza 8mcg for this particular indication as it could provide a treatment option to many adult women suffering from irritable bowel syndrome with constipation."
Source: Datamonitor
Related Articles
- Sucampo Pharmaceuticals Initiates Phase 2 Trial of Cobiprostone for the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
- Low Levels of Diagnosis and New Biological Approaches to Treatment Indicate a Positive Future for Gastrointestinal Drugs
- Sucampo Pharmaceuticals Announces the Initiation of Filings of Marketing Authorization Applications for AMITIZA(R) in Europe
- Learn About Recent Gastrointestinal Drug Discoveries
- Sucampo Pharma, Ltd., A Subsidiary of Sucampo Pharmaceuticals, Inc. Appoints Kunihiko Soneoka As President and CEO
- Verispan Recognizes Sucampo Pharmaceuticals As a Top 20 Pharmaceutical Company in Promoting to the U.S. Nursing Home Market
- Sucampo Pharmaceuticals Announces CFO Transition in 2008; Elects New Independent Director
- Study Supports Sucampo's Amitiza in IBS
- Takeda and TAP to Promote Sucampo's AMITIZA(R) in the United States
- Sucampo's Amitiza(TM) is Finalist for The Scrip Award for Best New Small-Molecule Drug in 2006
User Comments (0)
RSS Feeds